Top Suppliers:I want be here
Related CAS#:
605-94-7 24663-35-2
25222-34-8 7704-04-3
7444-53-3 60684-33-5
213011-88-2 727-81-1
2394-68-5 303-97-9
1158522-08-7 1892586-50-3
940364-43-2 134104-43-1
131615-57-1 6906-52-1
1804516-84-4 930439-75-1
1018584-77-4 1375289-11-4

605-94-7

605-94-7 structure
605-94-7 structure
  • Name: Ubiquinone Q0
  • Chemical Name: ubiquinone-0
  • CAS Number: 605-94-7
  • Molecular Formula: C9H10O4
  • Molecular Weight: 182.173
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2019-01-13 12:14:22
  • Modify Date: 2024-01-02 15:14:16
  • Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling[1][2][3].
Name ubiquinone-0
Synonyms 1,2,3-Dimethoxy-5-methyl-1,4-benzoquinone
2,5-Cyclohexadiene-1,4-dione, 2,3-dimethoxy-5-methyl-
EINECS 210-100-8
2,3-dimethoxy-5-methyl-1,4-benzoquinone
2,3-Dimethoxy-5-methylcyclohexa-2,5-dien-1,4-dion
p-Benzoquinone, 2,3-dimethoxy-5-methyl-
2,3-Dimethoxy-5-Methyl-p-Benzoquinone
Ubiquinone Q0
2,3-dimethoxy-5-methylcyclohexa-2,5-diene-1,4-dione
MFCD00001595
Description Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling[1][2][3].
Related Catalog
In Vitro Coenzyme Q0 (0-40 µM; 24 h) and inhibits viability and growth of human ovarian carcinoma cells[1]. Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) has anti-proliferative activity through induction of G2/M cell-cycle arrest and reduction of cell-cycle regulatory proteins[1]. Coenzyme Q0 (CoQ0) (0-30 µM; 0-30 min; SKOV-3 cells) increases intracellular ROS levels to promote SKOV-3 cell death[1]. Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) induces autophagy by increase accumulation of LC3-II, GFP-LC3 puncta, AVOs formation and Beclin-1/Bcl-2 dysregulation[1]. Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) induces apoptosis by mitochondrial (caspase-3, PARP and Bax/Bcl-2 dysregulation) and ER stress (caspase-12 and Hsp70) signals[1]. Coenzyme Q0 (CoQ0) (30 µM; 24 h; SKOV-3 cells) suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms[1]. Coenzyme Q0 (CoQ0) (0-10 µM; 0.5-18 h; RAW264.7 cells) regulates NFκB/AP-1 activation and enhances Nrf2 stabilization[2]. Coenzyme Q0 (CoQ0) (5 µM; 0-12 h; EA.hy 926 cells) has anti-angiogenic activity in EA.hy 926 cells[3]. Cell Viability Assay[1] Cell Line: SKOV-3, A2780 and A2870/CP70 cells Concentration: 0, 10, 20, 30 and 40 µM Incubation Time: 24 hours Result: Decreased viability with the IC50 values of 26.6 µM, 27.3 µM and 28.4 µM for SKOV-3, A2780 and A2870/CP70 cells, respectively. Cell Cycle Analysis[1] Cell Line: SKOV-3, A2780 and A2870/CP70 cells Concentration: 0, 10, 20 and 30 µM Incubation Time: 24 hours Result: Arrested cell cycle at G2/M phase and reduced cell-cycle proteins in SKOV-3 cells. Apoptosis Analysis[1] Cell Line: SKOV-3, A2780 and A2870/CP70 cells Concentration: 0, 5, 15 and 30 µM Incubation Time: 24 hours Result: Promoted the conversion of LC3–1 to LC3-II and increased the LC3-II accumulation. Increased Bax/Bcl-2 ratio in a dose-dependent manner. Apoptosis Analysis[1] Cell Line: SKOV-3 cells Concentration: 0, 10, 20 and 30 µM Incubation Time: 24 hours Result: Had the percentage of early apoptotic cells are 25.1%, 34% and 36% for 10, 20 and 30 µM, respectively. Western Blot Analysis[1] Cell Line: SKOV-3 cells Concentration: 0, 5, 15 and 30 µM Incubation Time: 24 hours Result: Activated of caspase-3 and cleavaged of PARP. Increased the expressions of caspase-12, HSP-70 and Bax in a dose-dependent manner, decreased the expressions of Bcl-2. Western Blot Analysis[1] Cell Line: SKOV-3 cells Concentration: 30 µM Incubation Time: 24 hours Result: Decreased the phosphorylated HER-2 (Y1221) levels, p-AKT (Ser473) and p-mTOR (S2448) levels. Western Blot Analysis[2] Cell Line: RAW264.7 cells Concentration: 0, 2.5, 5 and 10 µM Incubation Time: 0.5-18 hours Result: Inhibited iNOS/COX-2 protein expressions with reductions of NO, PGE2, TNF-α and IL-1β secretions. Western Blot Analysis[3] Cell Line: EA.hy 926 cells Concentration: 5 µM Incubation Time: 0, 1, 3, 6 and 12 hours Result: Increased expressions of heme oxygenase-1 (HO-1) and γ-glutamylcysteine synthetase (γ-GCLC), inhibits protein expressions of matrix metalloproteinase-9 (MMP-9), reduces TNF-α-induced nuclear translocation and transcriptional activation of nuclear factor-κB (NF-κB).
In Vivo Coenzyme Q0 (CoQ0) (1.5 and 2.5 mg/kg; i.p.; once every four days, for 52 d) suppresses tumor growth in SKOV-3 xenografted nude mice[1]. Coenzyme Q0(CoQ0) (5 mg/kg; p.o.; for 4 h) has anti-inflammatory activities through Nrf2 activation and NFκB inhibition in liver and spleen of LPS-treated mice[2]. Animal Model: SKOV-3 xenografted nude mice[1] Dosage: 1.5 and 2.5 mg/kg Administration: Intraperitoneal injection; Once every four days, for 52 days Result: Inhibited the tumor growth at 1.5 and 2.5 mg/kg. Animal Model: LPS-treated female FVB mice[2] Dosage: 5 mg/kg Administration: Oral administration; for 4 hours Result: Down-regulates inflammatory genes in liver and spleen tissues of LPS injected mice.
References

[1]. Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.

[2]. Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.

[3]. Yang HL, et, al. Anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling in TNF-α-activated human endothelial cells. Biochem Pharmacol. 2015 Nov 1;98(1):144-56.
Density 1.2±0.1 g/cm3
Boiling Point 331.4±42.0 °C at 760 mmHg
Melting Point 58-60 °C(lit.)
Molecular Formula C9H10O4
Molecular Weight 182.173
Flash Point 148.6±27.9 °C
Exact Mass 182.057907
PSA 52.60000
LogP 0.12
Vapour Pressure 0.0±0.7 mmHg at 25°C
Index of Refraction 1.498
Storage condition 2-8°C
Stability Stable. Combustible. Incompatible with strong oxidizing agents, reducing agents.
Symbol GHS07
GHS07
Signal Word Warning
Hazard Statements H315-H319-H335
Precautionary Statements P261-P305 + P351 + P338
Personal Protective Equipment dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes Xi:Irritant;
Risk Phrases R36/37/38
Safety Phrases S26-S36
RIDADR NONH for all modes of transport
WGK Germany 2

Chemsrc provides CAS#:605-94-7 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 605-94-7 | Chemsrc address: https://www.chemsrc.com/en/baike/311659.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved